泌尿科医生,肿瘤科医生和护士从业经验与主流基因检测转移性前列腺癌。

IF 5.1 2区 医学 Q1 ONCOLOGY
Michiel Vlaming, Margreet G E M Ausems, Lambertus A L M Kiemeney, Gina Schijven, Harm H E van Melick, M Arjen Noordzij, Diederik M Somford, Henk G van der Poel, Carl J Wijburg, Bart P Wijsman, Robert J Hoekstra, Reindert J A van Moorselaar, Bart P J van Bezooijen, Richard P Meijer, Martijn B Busstra, H Pieter van den Berg, Debbie G J Robbrecht, Benjamin H J Doornweerd, Eveline M A Bleiker, Inge M van Oort
{"title":"泌尿科医生,肿瘤科医生和护士从业经验与主流基因检测转移性前列腺癌。","authors":"Michiel Vlaming, Margreet G E M Ausems, Lambertus A L M Kiemeney, Gina Schijven, Harm H E van Melick, M Arjen Noordzij, Diederik M Somford, Henk G van der Poel, Carl J Wijburg, Bart P Wijsman, Robert J Hoekstra, Reindert J A van Moorselaar, Bart P J van Bezooijen, Richard P Meijer, Martijn B Busstra, H Pieter van den Berg, Debbie G J Robbrecht, Benjamin H J Doornweerd, Eveline M A Bleiker, Inge M van Oort","doi":"10.1038/s41391-024-00925-w","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>International guidelines recommend germline genetic testing for men with metastatic prostate cancer. If offered to all patients by genetic healthcare professionals, there will be insufficient capacity to cope with the high patient numbers. In a mainstreaming pathway, non-genetic healthcare professionals (ngHCPs) discuss and order germline genetic testing instead of referring patients to genetic healthcare professionals. We aimed to evaluate the experience of ngHCPs with pre-test genetic counselling and to explore the feasibility from the ngHCPs' perspective.</p><p><strong>Methods: </strong>We carried out a prospective cohort study in 15 hospitals in the Netherlands. All participating ngHCPs (i.e. urologists, medical oncologists, specialist nurses and nurse practitioners) completed an online training module of 45 min. The ngHCPs completed a questionnaire both before the training and at three and nine months after it. Paired analyses were used to compare the first with the last questionnaires on attitude, confidence in the ability to discuss and order germline genetic testing, and perceived and actual knowledge of genetics and genetic testing.</p><p><strong>Results: </strong>167 ngHCPs were invited to participate of whom 69 completed the first questionnaire and started or completed the last one. They had a positive attitude towards offering genetic testing themselves. After nine months of providing pre-test genetic counselling, significantly more ngHCPs considered mainstreaming helpful (94% after versus 81% before, p = 0.01). Both perceived and actual knowledge increased significantly. Pre-test genetic counselling took less than 10 minutes for 82% of ngHCPs and the majority (88%) were in favour of continuing the mainstream pathway. Only six participating ngHCPs considered mainstreaming possible without completing a training module beforehand.</p><p><strong>Conclusions: </strong>After completing a short online training module, ngHCPs feel well-prepared to discuss germline genetic testing with metastatic prostate cancer patients.</p>","PeriodicalId":20727,"journal":{"name":"Prostate Cancer and Prostatic Diseases","volume":" ","pages":""},"PeriodicalIF":5.1000,"publicationDate":"2024-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Experience of urologists, oncologists and nurse practitioners with mainstream genetic testing in metastatic prostate cancer.\",\"authors\":\"Michiel Vlaming, Margreet G E M Ausems, Lambertus A L M Kiemeney, Gina Schijven, Harm H E van Melick, M Arjen Noordzij, Diederik M Somford, Henk G van der Poel, Carl J Wijburg, Bart P Wijsman, Robert J Hoekstra, Reindert J A van Moorselaar, Bart P J van Bezooijen, Richard P Meijer, Martijn B Busstra, H Pieter van den Berg, Debbie G J Robbrecht, Benjamin H J Doornweerd, Eveline M A Bleiker, Inge M van Oort\",\"doi\":\"10.1038/s41391-024-00925-w\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>International guidelines recommend germline genetic testing for men with metastatic prostate cancer. If offered to all patients by genetic healthcare professionals, there will be insufficient capacity to cope with the high patient numbers. In a mainstreaming pathway, non-genetic healthcare professionals (ngHCPs) discuss and order germline genetic testing instead of referring patients to genetic healthcare professionals. We aimed to evaluate the experience of ngHCPs with pre-test genetic counselling and to explore the feasibility from the ngHCPs' perspective.</p><p><strong>Methods: </strong>We carried out a prospective cohort study in 15 hospitals in the Netherlands. All participating ngHCPs (i.e. urologists, medical oncologists, specialist nurses and nurse practitioners) completed an online training module of 45 min. The ngHCPs completed a questionnaire both before the training and at three and nine months after it. Paired analyses were used to compare the first with the last questionnaires on attitude, confidence in the ability to discuss and order germline genetic testing, and perceived and actual knowledge of genetics and genetic testing.</p><p><strong>Results: </strong>167 ngHCPs were invited to participate of whom 69 completed the first questionnaire and started or completed the last one. They had a positive attitude towards offering genetic testing themselves. After nine months of providing pre-test genetic counselling, significantly more ngHCPs considered mainstreaming helpful (94% after versus 81% before, p = 0.01). Both perceived and actual knowledge increased significantly. Pre-test genetic counselling took less than 10 minutes for 82% of ngHCPs and the majority (88%) were in favour of continuing the mainstream pathway. Only six participating ngHCPs considered mainstreaming possible without completing a training module beforehand.</p><p><strong>Conclusions: </strong>After completing a short online training module, ngHCPs feel well-prepared to discuss germline genetic testing with metastatic prostate cancer patients.</p>\",\"PeriodicalId\":20727,\"journal\":{\"name\":\"Prostate Cancer and Prostatic Diseases\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":5.1000,\"publicationDate\":\"2024-12-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Prostate Cancer and Prostatic Diseases\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1038/s41391-024-00925-w\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Prostate Cancer and Prostatic Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41391-024-00925-w","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:国际指南推荐对男性转移性前列腺癌患者进行生殖系基因检测。如果由遗传保健专业人员向所有患者提供,那么将没有足够的能力来处理大量患者。在主流途径中,非遗传保健专业人员(ngHCPs)讨论和订购种系基因检测,而不是将患者转介给遗传保健专业人员。我们的目的是评估ngHCPs在测试前遗传咨询方面的经验,并从ngHCPs的角度探讨可行性。方法:我们在荷兰的15家医院进行了一项前瞻性队列研究。所有参与的全国泌尿科医师(即泌尿科医师、肿瘤内科医师、专科护士和执业护士)都完成了45分钟的在线培训模块。在培训前和培训后的3个月和9个月,初级保健医师完成了一份调查问卷。配对分析用于比较第一份问卷和最后一份问卷的态度,对讨论和订购生殖系基因检测能力的信心,以及对遗传学和基因检测的感知和实际知识。结果:167名初级保健医师被邀请参加,其中69人完成了第一份问卷,并开始或完成了最后一份问卷。他们对自己提供基因检测持积极态度。在提供检测前遗传咨询9个月后,更多的ngHCPs认为主流化有帮助(94%后vs 81%前,p = 0.01)。感知知识和实际知识都显著增加。82%的nghcp在检测前进行遗传咨询不到10分钟,大多数(88%)支持继续主流途径。只有6个参与的国家卫生保健cps认为在不事先完成培训模块的情况下实现主流化是可能的。结论:在完成了一个简短的在线培训模块后,ngHCPs对与转移性前列腺癌患者讨论生殖系基因检测做好了充分的准备。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Experience of urologists, oncologists and nurse practitioners with mainstream genetic testing in metastatic prostate cancer.

Background: International guidelines recommend germline genetic testing for men with metastatic prostate cancer. If offered to all patients by genetic healthcare professionals, there will be insufficient capacity to cope with the high patient numbers. In a mainstreaming pathway, non-genetic healthcare professionals (ngHCPs) discuss and order germline genetic testing instead of referring patients to genetic healthcare professionals. We aimed to evaluate the experience of ngHCPs with pre-test genetic counselling and to explore the feasibility from the ngHCPs' perspective.

Methods: We carried out a prospective cohort study in 15 hospitals in the Netherlands. All participating ngHCPs (i.e. urologists, medical oncologists, specialist nurses and nurse practitioners) completed an online training module of 45 min. The ngHCPs completed a questionnaire both before the training and at three and nine months after it. Paired analyses were used to compare the first with the last questionnaires on attitude, confidence in the ability to discuss and order germline genetic testing, and perceived and actual knowledge of genetics and genetic testing.

Results: 167 ngHCPs were invited to participate of whom 69 completed the first questionnaire and started or completed the last one. They had a positive attitude towards offering genetic testing themselves. After nine months of providing pre-test genetic counselling, significantly more ngHCPs considered mainstreaming helpful (94% after versus 81% before, p = 0.01). Both perceived and actual knowledge increased significantly. Pre-test genetic counselling took less than 10 minutes for 82% of ngHCPs and the majority (88%) were in favour of continuing the mainstream pathway. Only six participating ngHCPs considered mainstreaming possible without completing a training module beforehand.

Conclusions: After completing a short online training module, ngHCPs feel well-prepared to discuss germline genetic testing with metastatic prostate cancer patients.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Prostate Cancer and Prostatic Diseases
Prostate Cancer and Prostatic Diseases 医学-泌尿学与肾脏学
CiteScore
10.00
自引率
6.20%
发文量
142
审稿时长
6-12 weeks
期刊介绍: Prostate Cancer and Prostatic Diseases covers all aspects of prostatic diseases, in particular prostate cancer, the subject of intensive basic and clinical research world-wide. The journal also reports on exciting new developments being made in diagnosis, surgery, radiotherapy, drug discovery and medical management. Prostate Cancer and Prostatic Diseases is of interest to surgeons, oncologists and clinicians treating patients and to those involved in research into diseases of the prostate. The journal covers the three main areas - prostate cancer, male LUTS and prostatitis. Prostate Cancer and Prostatic Diseases publishes original research articles, reviews, topical comment and critical appraisals of scientific meetings and the latest books. The journal also contains a calendar of forthcoming scientific meetings. The Editors and a distinguished Editorial Board ensure that submitted articles receive fast and efficient attention and are refereed to the highest possible scientific standard. A fast track system is available for topical articles of particular significance.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信